ProShare Advisors
ROIV icon

ProShare Advisors’s Roivant Sciences ROIV Stock Holding History

ProShare Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
41,371
-8,731
-17% -$258K ﹤0.01% 730
2026
Q1 		$1.39M Buy
50,102
+1,812
+4% +$46.5K ﹤0.01% 733
2025
Q4 		$1.05M Buy
48,290
+5,664
+13% +$112K ﹤0.01% 810
2025
Q3 		$645K Sell
42,626
-1,426
-3% -$17.7K ﹤0.01% 973
2025
Q2 		$496K Sell
44,052
-6,073
-12% -$65.8K ﹤0.01% 1136
2025
Q1 		$506K Sell
50,125
-4,459
-8% -$48.2K ﹤0.01% 1091
2024
Q4 		$646K Sell
54,584
-8,136
-13% -$96.2K ﹤0.01% 1128
2024
Q3 		$724K Buy
62,720
+1,138
+2% +$13K ﹤0.01% 928
2024
Q2 		$651K Buy
61,582
+5,108
+9% +$56K ﹤0.01% 858
2024
Q1 		$595K Buy
56,474
+5,108
+10% +$55.1K ﹤0.01% 985
2023
Q4 		$577K Buy
51,366
+914
+2% +$8.91K ﹤0.01% 961
2023
Q3 		$589K Buy
50,452
+1,379
+3% +$15.6K ﹤0.01% 857
2023
Q2 		$495K Sell
49,073
-3,507
-7% -$31.4K ﹤0.01% 962
2023
Q1 		$388K Sell
52,580
-7,416
-12% -$61.1K ﹤0.01% 1047
2022
Q4 		$479K Buy
+59,996
New +$334K ﹤0.01% 982

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ProShare Advisors's ROIV Position: Q2 2026 in Review

ProShare Advisors reduced its Roivant Sciences (ROIV) stake by 17% in Q2 2026, selling an estimated $258K and leaving 41,371 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #730.

ProShare Advisors first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • ProShare Advisors held 41,371 shares of Roivant Sciences worth $1.46M as of Q2 2026.
  • ProShare Advisors sold 8,731 Roivant Sciences shares in Q2 2026, an estimated $258K.
  • Roivant Sciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #730 holding.
  • ProShare Advisors first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.